Type 2 Diabetes Mellitus
Conditions
Keywords
diabetes, type 2
Brief summary
This study is designed to evaluate the safety and efficacy of PN2034 administered to type 2 diabetics on concomitant rosiglitazone and metformin (or Avandamet) therapy as measured by change in glycosylated hemoglobin (HbA1c) levels from baseline to Week 12. Also the study will evaluate the effect of PN2034 on glucose control as measured by fasting plasma glucose (FPG) and on fasting lipid levels: triglycerides, total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), and very low-density lipoproteins (VLDL).
Interventions
Sponsors
Wellstat Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
21 Years to 72 Years
Healthy volunteers
No
Inclusion criteria
* diagnosed with type 2 diabetes mellitus * 21 to 72 years of age * taking rosiglitazone and metformin (or Avandamet) for at least 3 months, and on a stable dose of rosiglitazone (or Avandamet) for at least 2 months * glycosylated hemoglobin (HbA1c) level of \>/=7.5% but \</=10.0% * fasting blood sugar level \>/= 125 mg/dL but \</= 279 mg/dL * BMI 26-43 kg/m2 * direct bilirubin \< 1.5x the upper limit of normal (ULN) * serum creatinine \< 1.5 mg/dL (males) or \< 1.4 mg/dL (females) * blood urea nitrogen (BUN)\</=40 mg/dL * all other clinical laboratory parameters (hematology, serum chemistry, and urinalysis) within normal limits or not clinically significant * ECG normal, or abnormalities not clinically significant * surgically sterile, postmenopausal, or using adequate contraception and have a negative pregnancy test at Screening * willing and able to sign an informed consent form
Exclusion criteria
* diagnosed with type 1 diabetes mellitus or has a history of ketoacidosis * treatment with insulin, TZDs (excluding rosiglitazone) or any other oral or injected antidiabetic (excluding metformin or Avandamet) within 3 months prior to screening or during study treatment * change in lipid-lowering medication within 2 months of screening * taken systemic corticosteroids within 1 month prior to screening or during study treatment * history of or current/active cardiovascular disease * significant current pulmonary conditions * significant thyroid disease * CPK value \> 3x ULN * a female who is pregnant or lactating * systolic BP \> 160 mm Hg or a diastolic BP \> 90 mm Hg at screening * previous or current history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to randomization * liver function tests (ALT, AST, ALP) \> 2 times ULN, or active liver disease at screening * history of positive HIV * positive hepatitis B test at screening * weight loss or gain \>/= 15 lbs within 3 months of screening * history of substance abuse (including alcohol abuse) within 2 years prior to screening * donated and/or received any blood or blood products within 3 months prior to randomization * taken an investigational study medication within 30 days prior to screening or during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
| Effect on HbA1c levels | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect on glucose control as measured by FPG | — |
| Effect on lipid levels | — |
Countries
United States
Outcome results
None listed